BioSpace News Archive

DURECT Corporation announced that the U.S. Food and Drug Administration has notified the Company that its Class 2 NDA resubmission for POSIMIR® will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee.

VBI Vaccines Inc. announced that the company’s abstract titled, “Trivalent hepatitis B vaccine yields superior seroprotection rates in adults: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety of a 3-Dose regimen of Sci-B-Vac™ and Engerix B®,” has been selected for a late-breaker oral presentation at IDWeek 2019™, in Washington, D.C., on Friday, October 4, 2019.

CNS Network and Hassman Research Institute have completed a strategic merger to form Apex Innovative Sciences, Inc..

Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), announced today it has received the $2 million upfront distribution fee pursuant to its global distribution agreement, entered into as of August 30, 2019, for the X-Series® product line.

Jackson T. “Steve” Stephens, Founder and CEO of Exoxemis, Inc. (www.exoxemis.com) announced the publication of a peer reviewed article, which he co-authored with Dr. Robert C. Allen just published in the Journal of Immunology Research titled Myeloperoxidase and Eosinophil Peroxidase Inhibit Endotoxin Activity and Increase Mouse Survival in a Lipopolysaccharide Lethal Dose 90% Model.

Walmart Inc. is suspending the sale of all over the counter ranitidine products in stores, clubs and online, including Zantac, Equate and Member’s Mark brands.

Scientists from the University of Texas at Dallas announced a groundbreaking new approach for improving control of prosthetics with the use of artificial intelligence (AI) at the 2019 IEEE International Symposium on Measurement and Control in Robotics Symposium this month.

Investment to accelerate growth and subscription offerings, continuing the momentum of Petplan’s strong 2019 performance

Lark recognized for achievements in chronic disease prevention

Delivers the Efficacy of an Injectable with the Convenience of a Nasal Spray